<br><br>**Title** Bayer Proposes $7.25 Billion Plan to Settle Roundup Cancer Cases A Potential Turning Point in a Costly Litigation Saga<br><br>Bayer, the German-based agrichemical giant, has proposed a class settlement of up to $7.25 billion to settle claims that its subsidiary Monsanto's Roundup weedkiller causes blood cancer. This potential settlement marks a significant milestone in Bayer's efforts to put an end to the costly litigation surrounding Roundup.<br><br>**The Proposal**<br><br>Under the proposed agreement, Monsanto would make a series of declining annual payments for up to 21 years. The deal still requires court approval, but if successful, it could bring relief to both Bayer and the thousands of claimants affected by Roundup.<br><br>**A Lengthy Litigation Saga**<br><br>Bayer has already spent more than $10 billion settling thousands of cases linked to Roundup since acquiring Monsanto in 2018. Despite ongoing legal battles, Bayer maintains that scientific studies and regulatory approvals demonstrate the weedkiller's safety.<br><br>**A Complex Legal Landscape**<br><br>The proposed settlement comes as the US Supreme Court prepares to hear Bayer's appeal against an award of $1.25 million to a Missouri man who claimed Roundup was responsible for his blood cancer. Bayer argues that it should be shielded from state lawsuits since the federal Environmental Protection Agency (EPA) approved the sale of Roundup without any warnings.<br><br>**A Call for Reform**<br><br>Bayer CEO Bill Anderson described the legal system as broken and emphasized the need for a more efficient and effective legal process to address complex cases like this one. The proposed settlement is necessary, he argued, despite ongoing uncertainty surrounding the Supreme Court's decision.<br><br>**Significance**<br><br>The proposed settlement could mark a turning point in Bayer's efforts to address the Roundup litigation saga. By providing a clear path forward for affected claimants, it could help reduce the financial burden on both Bayer and the thousands of individuals impacted by Roundup.<br><br>**Key Takeaways**<br><br>* Bayer has proposed a class settlement of up to $7.25 billion to settle claims that its subsidiary Monsanto's Roundup weedkiller causes blood cancer.<br>* The deal would require court approval but could provide relief to both Bayer and affected claimants.<br>* The proposal comes as the US Supreme Court prepares to hear Bayer's appeal against an award of $1.25 million to a Missouri man who claimed Roundup was responsible for his blood cancer.<br><br>**Conclusion**<br><br>Bayer's proposed settlement is a significant development in its efforts to address the Roundup litigation saga. While it remains to be seen whether the deal will ultimately succeed, it marks an important step towards providing relief to affected claimants and reducing the financial burden on both Bayer and the thousands of individuals impacted by Roundup.<br><br>**Matters for Journalists**<br><br>* The proposed settlement could have significant implications for the future of Roundup litigation.<br>* The case highlights the complexities surrounding the safety of glyphosate-based herbicides like Roundup.<br>* The proposal underscores the need for a more efficient and effective legal system to address complex cases like this one.<br><br>**Keywords** Bayer, Monsanto, Roundup, glyphosate, cancer, lawsuit, settlement, Supreme Court.
--
Disclaimer:
*The information
in this electronic message is privileged and
confidential, intended only
for use of the individual or entity named as
addressee and recipient.
If you are not the addressee indicated in this
message (or responsible
for delivery of the message
to such person), you
may not copy, use, disseminate or deliver this
message. In such case, you
should immediately delete this e-mail and
notify the sender by reply
e-mail. Please advise immediately if you or
your employer do not consent
to Internet e-mail
for messages of this kind. Opinions, conclusions and
other information
expressed in this message are not given, nor endorsed by
and are not the
responsibility of *USTP* unless otherwise indicated by an
authorized representative of *USTP* independent of this message.*
0 Comments